Although statins, ezetimibe, and PCSK9 inhibitors are the standard of care for coronary artery disease, many novel LDL cholesterol–lowering drugs, such as inclisiran recently approved by the FDA, may transform the care of patients who are at risk of life-threatening coronary events (37, 38). This evidence concerns the gene PCSK9 and coronary artery disorder.